{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=10", "query": { "condition": "Neuroendocrine Carcinoma", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 946, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Carcinoma&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T05:26:04.730Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Adult Primary Liver Cancer", "Anaplastic Thyroid Cancer", "Bone Metastases", "Carcinoma of the Appendix", "Distal Urethral Cancer", "Fallopian Tube Cancer", "Gastrinoma", "Glucagonoma", "Inflammatory Breast Cancer", "Insulinoma", "Liver Metastases", "Localized Unresectable Adult Primary Liver Cancer", "Lung Metastases", "Male Breast Cancer", "Malignant Pericardial Effusion", "Malignant Pleural Effusion", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Parathyroid Cancer", "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter", "Newly Diagnosed Carcinoma of Unknown Primary", "Occult Non-small Cell Lung Cancer", "Pancreatic Polypeptide Tumor", "Primary Peritoneal Cavity Cancer", "Proximal Urethral Cancer", "Pulmonary Carcinoid Tumor", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adrenocortical Carcinoma", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Bladder Cancer", "Recurrent Breast Cancer", "Recurrent Carcinoma of Unknown Primary", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Cancer", "Recurrent Extrahepatic Bile Duct Cancer", "Recurrent Gallbladder Cancer", "Recurrent Gastric Cancer", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Pancreatic Cancer", "Recurrent Parathyroid Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Renal Cell Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Small Intestine Cancer", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Thyroid Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Recurrent Vaginal Cancer", "Recurrent Vulvar Cancer", "Skin Metastases", "Small Intestine Adenocarcinoma", "Somatostatinoma", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Adrenocortical Carcinoma", "Stage III Bladder Cancer", "Stage III Cervical Cancer", "Stage III Colon Cancer", "Stage III Endometrial Carcinoma", "Stage III Esophageal Cancer", "Stage III Follicular Thyroid Cancer", "Stage III Gastric Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Ovarian Epithelial Cancer", "Stage III Pancreatic Cancer", "Stage III Papillary Thyroid Cancer", "Stage III Prostate Cancer", "Stage III Rectal Cancer", "Stage III Renal Cell Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IIIA Anal Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Anal Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Adrenocortical Carcinoma", "Stage IV Anal Cancer", "Stage IV Bladder Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Gastric Cancer", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Pancreatic Cancer", "Stage IV Papillary Thyroid Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer", "Stage IVB Vulvar Cancer", "Thyroid Gland Medullary Carcinoma", "Unresectable Extrahepatic Bile Duct Cancer", "Unresectable Gallbladder Cancer", "Urethral Cancer Associated With Invasive Bladder Cancer", "WDHA Syndrome" ], "interventions": [ { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" }, { "name": "ABI-007/carboplatin/trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-10-13T05:26:04.730Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004074" }, { "nct_id": "NCT00416949", "title": "Iodine I 131 in Treating Patients With Thyroid Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Patient-specific dosimetry", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 9, "start_date": "2006-04", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-10-13T05:26:04.730Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00416949" }, { "nct_id": "NCT02988817", "title": "Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Cervical Cancer", "Endometrial Cancer", "Non Small Cell Lung Cancer (NSCLC)", "Thyroid Cancer", "Melanoma", "Sarcoma", "Solid Tumors" ], "interventions": [ { "name": "Enapotamab vedotin (HuMax-AXL-ADC)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 306, "start_date": "2016-11-23", "completion_date": "2021-11-12", "has_results": true, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-10-13T05:26:04.730Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02988817" }, { "nct_id": "NCT01262235", "title": "A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Neuroendocrine Tumors", "NET", "Adrenocortical Carcinoma", "ACC" ], "interventions": [ { "name": "TKM-080301", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arbutus Biopharma Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2010-12", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2019-01-16", "last_synced_at": "2026-10-13T05:26:04.730Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Tampa, Florida • Iowa City, Iowa + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01262235" }, { "nct_id": "NCT00003308", "title": "Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer", "Melanoma (Skin)", "Metastatic Cancer", "Ovarian Cancer", "Sarcoma" ], "interventions": [ { "name": "stereotactic radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "1999-02-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-06-22", "last_synced_at": "2026-10-13T05:26:04.730Z", "location_count": 11, "location_summary": "Des Moines, Iowa • Kalamazoo, Michigan • Papillion, Nebraska + 5 more", "locations": [ { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Kalamazoo", "state": "Michigan" }, { "city": "Papillion", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003308" }, { "nct_id": "NCT03220009", "title": "Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Carcinoma", "Esophageal Carcinoma", "Mucosal Melanoma", "Mucosal Melanoma of the Head and Neck", "Oral Cavity Mucosal Melanoma", "Recurrent Melanoma", "Stage II Vulvar Cancer AJCC v7", "Stage III Vulvar Cancer AJCC v7", "Stage IIIA Vulvar Cancer AJCC v7", "Stage IIIB Vulvar Cancer AJCC v7", "Stage IIIC Vulvar Cancer AJCC v7", "Stage IV Oral Cavity Cancer AJCC v6 and v7", "Stage IV Vulvar Cancer AJCC v7", "Stage IVA Oral Cavity Cancer AJCC v6 and v7", "Stage IVB Oral Cavity Cancer AJCC v6 and v7", "Stage IVC Oral Cavity Cancer AJCC v6 and v7", "Vaginal Carcinoma" ], "interventions": [ { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-11-03", "completion_date": "2021-07-01", "has_results": false, "last_update_posted_date": "2018-10-03", "last_synced_at": "2026-10-13T05:26:04.730Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03220009" }, { "nct_id": "NCT02831933", "title": "Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Squamous Cell Carcinoma Stage IV", "Nonsquamous Nonsmall Cell Neoplasm of Lung", "Metastatic Uveal Melanoma" ], "interventions": [ { "name": "ADV/HSV-tk", "type": "BIOLOGICAL" }, { "name": "Valacyclovir", "type": "DRUG" }, { "name": "SBRT", "type": "RADIATION" }, { "name": "nivolumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Eric Bernicker, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2017-02-15", "completion_date": "2020-11-05", "has_results": true, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-13T05:26:04.730Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02831933" }, { "nct_id": "NCT00132704", "title": "An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ovarian Neoplasms", "Colorectal Neoplasms", "Melanoma", "Small Cell Lung Cancer", "Liposarcoma" ], "interventions": [ { "name": "Ionizing radiation (IR) therapy", "type": "RADIATION" }, { "name": "Ionizing radiation (IR)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 149, "start_date": "2004-08", "completion_date": "2014-07", "has_results": false, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-10-13T05:26:04.730Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00132704" }, { "nct_id": "NCT03093116", "title": "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumors", "Metastatic Solid Tumors" ], "interventions": [ { "name": "Oral repotrectinib (TPX-0005)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Turning Point Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 500, "start_date": "2017-03-07", "completion_date": "2028-02-29", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-10-13T05:26:04.730Z", "location_count": 49, "location_summary": "Duarte, California • Glendale, California • La Jolla, California + 36 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03093116" }, { "nct_id": "NCT04069299", "title": "Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neuroendocrine Carcinoma" ], "interventions": [ { "name": "68Ga-DOTATATE", "type": "DRUG" }, { "name": "Positron Emission Tomography (PET) Scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-09-25", "completion_date": "2025-06-02", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-10-13T05:26:04.730Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04069299" } ] }